{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:28:20Z","timestamp":1792787300301,"version":"4.5.0"},"reference-count":42,"publisher":"BMJ","issue":"10","funder":[{"name":"Parkinson UK","award":["G-1403"],"award-info":[{"award-number":["G-1403"]}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/M006646\/1"],"award-info":[{"award-number":["MR\/M006646\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/N028651\/1"],"award-info":[{"award-number":["MR\/N028651\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2019,5,1]]},"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      <jats:italic>GBA1<\/jats:italic>\n                      mutations are a frequent risk factor for Parkinson disease (PD). The aim of this study is to evaluate clinical features in a group of\n                      <jats:italic>GBA1<\/jats:italic>\n                      mutation\u2013positive individuals over a 6-year follow-up.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This is a longitudinal study on a cohort of\n                      <jats:italic>GBA1<\/jats:italic>\n                      -positive carriers. We enrolled 31 patients with Gaucher disease type 1 (GD), 29\n                      <jats:italic>GBA1<\/jats:italic>\n                      heterozygous carriers (Het\n                      <jats:italic>GBA<\/jats:italic>\n                      group) and 30 controls (HC) at baseline and followed them for 6\u2009years. We assessed baseline motor and non-motor signs of PD in all subjects using clinical questionnaires and scales (reduced Unified Multiple System Atrophy Rating Scale (UMSARS), Montreal Cognitive assessment (MoCA), University of Pennsylvania Smell Identification Test (UPSIT), REM Sleep Behavior Disorder screening questionnaire (RBDsq), Movement Disorders Society Unified Parkinson\u2019s Disease Rating Scale motor subscale (MDS-UPDRS III) and Beck Depression Inventory (BDI). We repeated these at the 6-year follow-up alongside venous blood sampling for measurement of glucocerebrosidase enzymatic activity (GCase). We explored whether the GCase activity level was altered in leucocytes of these subjects and how it was related to development of PD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We observed a significant worsening in UMSARS, RBDsq, MDS-UPDRS III and BDI scores at the 6-year follow-up compared with baseline in both the GD and Het\n                      <jats:italic>GBA<\/jats:italic>\n                      groups. Intergroup comparisons showed that GD subjects had significantly worse scores in UPSIT, UMSARS, MoCA and MDS-UPDRS III than HC, while Het\n                      <jats:italic>GBA<\/jats:italic>\n                      displayed worse outcomes in UPSIT and MDS-UPDRS III compared with HC. In\n                      <jats:italic>GBA1<\/jats:italic>\n                      mutation\u2013positive individuals (Het\n                      <jats:italic>GBA<\/jats:italic>\n                      and GD), an UPSIT score of 23 at baseline was correlated with worse outcome at 6 years in UPSIT, MoCA, MDS-UPDRS III and BDI.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      In this 6-year-long longitudinal study,\n                      <jats:italic>GBA1<\/jats:italic>\n                      mutation\u2013positive subjects showed a worsening in motor and non-motor prodromal PD features.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jnnp-2019-320394","type":"journal-article","created":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T17:34:04Z","timestamp":1561052044000},"page":"1091-1097","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":56,"title":["Evolution of prodromal parkinsonian features in a cohort of\n                    <i>GBA<\/i>\n                    mutation-positive individuals: a 6-year longitudinal study"],"prefix":"10.1136","volume":"90","author":[{"given":"Micol","family":"Avenali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Toffoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Mullin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisdair","family":"McNeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derralynn A","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Blandini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3018-3966","authenticated-orcid":false,"given":"Anthony H V","family":"Schapira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,6,20]]},"reference":[{"key":"2024111107500839000_90.10.1091.1","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","article-title":"Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease","volume":"361","author":"Sidransky","year":"2009","journal-title":"N Engl J Med Overseas Ed"},{"key":"2024111107500839000_90.10.1091.2","doi-asserted-by":"publisher","DOI":"10.1038\/nature13476"},{"key":"2024111107500839000_90.10.1091.3","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/89.9.691"},{"key":"2024111107500839000_90.10.1091.4","doi-asserted-by":"publisher","DOI":"10.1006\/mgme.2001.3201"},{"key":"2024111107500839000_90.10.1091.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2003.11.004"},{"key":"2024111107500839000_90.10.1091.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2007.03.004"},{"key":"2024111107500839000_90.10.1091.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2011.06.015"},{"key":"2024111107500839000_90.10.1091.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2009.12.007"},{"key":"2024111107500839000_90.10.1091.9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2012.03817.x"},{"key":"2024111107500839000_90.10.1091.10","doi-asserted-by":"crossref","unstructured":"CB D , Tung JY , Dorfman E , et al . Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson\u2019s disease. PLoS Genet 2011;7.","DOI":"10.1371\/journal.pgen.1002141"},{"key":"2024111107500839000_90.10.1091.11","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3043"},{"key":"2024111107500839000_90.10.1091.12","doi-asserted-by":"publisher","DOI":"10.1038\/ng.487"},{"key":"2024111107500839000_90.10.1091.13","doi-asserted-by":"publisher","DOI":"10.1038\/ng.485"},{"key":"2024111107500839000_90.10.1091.14","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awt367"},{"key":"2024111107500839000_90.10.1091.15","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/mds.26200","article-title":"Plasma oligomeric alpha-synuclein is associated with glucocerebrosidase activity in Gaucher disease","volume":"30","author":"Nuzhnyi","year":"2015","journal-title":"Mov Disord"},{"key":"2024111107500839000_90.10.1091.16","unstructured":"Horowitz M , Elstein D , Zimran A , et al . New directions in Gaucher disease. Hum Mutat 2016:1\u201316."},{"key":"2024111107500839000_90.10.1091.17","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1177\/1073858417748875","article-title":"Glucocerebrosidase and Parkinson disease: molecular, clinical, and therapeutic implications","volume":"24","author":"Balestrino","year":"2018","journal-title":"Neuroscientist"},{"key":"2024111107500839000_90.10.1091.18","doi-asserted-by":"publisher","DOI":"10.1002\/MDS.26616"},{"key":"2024111107500839000_90.10.1091.19","doi-asserted-by":"publisher","DOI":"10.1002\/mds.24945"},{"key":"2024111107500839000_90.10.1091.20","doi-asserted-by":"crossref","unstructured":"Beavan M , McNeill A , Proukakis C , et al . Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation\u2013positive cohort. JAMA Neurol 2015;72.doi:10.1001\/jamaneurol.2014.2950","DOI":"10.1001\/jamaneurol.2014.2950"},{"key":"2024111107500839000_90.10.1091.21","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22340"},{"key":"2024111107500839000_90.10.1091.22","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181fc29c9"},{"key":"2024111107500839000_90.10.1091.23","unstructured":"Doty RL . The smell identification test administration manual: 3rd edition. 3rd edn, 1983."},{"key":"2024111107500839000_90.10.1091.24","unstructured":"Doty R . Changes in the interpretation of normative clinical boundaries for the smell identification test."},{"key":"2024111107500839000_90.10.1091.25","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(200011)15:6<1221::AID-MDS1024>3.0.CO;2-H"},{"key":"2024111107500839000_90.10.1091.26","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21740"},{"key":"2024111107500839000_90.10.1091.27","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awp044"},{"key":"2024111107500839000_90.10.1091.28","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.parkreldis.2015.12.002","article-title":"Leukocyte glucocerebrosidase and \u03b2-hexosaminidase activity in sporadic and genetic Parkinson disease","volume":"23","author":"Kim","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"key":"2024111107500839000_90.10.1091.29","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/mds.26433","article-title":"Lysosomal alterations in peripheral blood mononuclear cells of Parkinson's disease patients","volume":"30","author":"Papagiannakis","year":"2015","journal-title":"Mov Disord"},{"key":"2024111107500839000_90.10.1091.30","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jpba.2013.12.027","article-title":"Development and application to clinical practice of a validated HPLC method for the analysis of \u03b2-glucocerebrosidase in Gaucher disease","volume":"91","author":"Colomer","year":"2014","journal-title":"J Pharm Biomed Anal"},{"key":"2024111107500839000_90.10.1091.31","doi-asserted-by":"crossref","unstructured":"Benjamini Y , Hochberg Y . Controlling the false discovery rate: a practical and powerful approach to multiple testing, 1995. Available: http:\/\/engr.case.edu\/ray_soumya\/mlrg\/controlling_fdr_benjamini95.pdf [Accessed 17 Mar 2019].","DOI":"10.1111\/j.2517-6161.1995.tb02031.x"},{"key":"2024111107500839000_90.10.1091.32","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26424"},{"key":"2024111107500839000_90.10.1091.33","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2010.52"},{"key":"2024111107500839000_90.10.1091.34","doi-asserted-by":"publisher","DOI":"10.1038\/nrn.2017.62"},{"key":"2024111107500839000_90.10.1091.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2011.05.003"},{"key":"2024111107500839000_90.10.1091.36","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2016.152"},{"key":"2024111107500839000_90.10.1091.37","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23614"},{"key":"2024111107500839000_90.10.1091.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2009.03.002"},{"key":"2024111107500839000_90.10.1091.39","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25772"},{"key":"2024111107500839000_90.10.1091.40","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awv179"},{"key":"2024111107500839000_90.10.1091.41","doi-asserted-by":"crossref","unstructured":"Atashrazm F , Hammond D , Perera G , et al . Reduced glucocerebrosidase activity in monocytes from patients with Parkinson's disease. Sci Rep 2018;8.doi:10.1038\/s41598-018-33921-x","DOI":"10.1038\/s41598-018-33921-x"},{"key":"2024111107500839000_90.10.1091.42","first-page":"158","article-title":"Leukocyte beta-glucosidase in homozygotes and heterozygotes for Gaucher disease","volume":"32","author":"Raghavan","year":"1980","journal-title":"Am J Hum Genet"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2019-320394","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T10:51:52Z","timestamp":1731322312000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2019-320394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,20]]},"references-count":42,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,9,12]]},"published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.1136\/jnnp-2019-320394"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2019-320394","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,20]]}}}